The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Kinome_2842     5-[2-(3,4-dihydroxyphenyl) ethenyl]benzene...

Synonyms: SureCN505561, AG-J-48945, KBioGR_000460, KBioSS_000460, ANW-43826, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C05901


High impact information on C05901


Chemical compound and disease context of C05901


Biological context of C05901

  • The agonist-induced tyrosine phosphorylation of the 42-/44-kD doublet was sensitive to the tyrosine kinase inhibitors genistein (100 mumol/L) and piceatannol (10 mumol/L) and was inhibited by the removal of Ca2+ from the extracellular medium [11].
  • This enhanced phagocytosis was abrogated by treatment of PMN with wortmannin, a phosphatidylinositol-3 kinase inhibitor, or with piceatannol, a Syk inhibitor, consistent with uptake through FcgammaR [12].
  • Depletion of Syk by small interfering RNA, expression of a dominant negative Syk mutant (Syk KD), or treatment with the Syk inhibitor piceatannol inhibited not only Stx-induced clathrin phosphorylation but also endocytosis of the toxin [13].
  • The MDA-MB-231 cells transfected with wild type Syk cDNA followed by treatment with piceatannol, a Syk inhibitor, enhanced cell motility and PI 3'-kinase activity [14].
  • Piceatannol, a selective inhibitor of p72(syk), enhanced Fc gammaRII tyrosine phosphorylation induced by Fc gammaRII cross-linking, whereas it attenuated the process in anti-CD9 mAb-induced platelet activation [15].

Anatomical context of C05901


Associations of C05901 with other chemical compounds


Gene context of C05901


Analytical, diagnostic and therapeutic context of C05901


  1. Syk-dependent mTOR activation in follicular lymphoma cells. Leseux, L., Hamdi, S.M., Al Saati, T., Capilla, F., Recher, C., Laurent, G., Bezombes, C. Blood (2006) [Pubmed]
  2. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Wieder, T., Prokop, A., Bagci, B., Essmann, F., Bernicke, D., Schulze-Osthoff, K., Dörken, B., Schmalz, H.G., Daniel, P.T., Henze, G. Leukemia (2001) [Pubmed]
  3. Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. Niles, R.M., Cook, C.P., Meadows, G.G., Fu, Y.M., McLaughlin, J.L., Rankin, G.O. J. Nutr. (2006) [Pubmed]
  4. ITAM-based interaction of ERM proteins with Syk mediates signaling by the leukocyte adhesion receptor PSGL-1. Urzainqui, A., Serrador, J.M., Viedma, F., Yáñez-Mó, M., Rodríguez, A., Corbí, A.L., Alonso-Lebrero, J.L., Luque, A., Deckert, M., Vázquez, J., Sánchez-Madrid, F. Immunity (2002) [Pubmed]
  5. Functional role for Syk tyrosine kinase in natural killer cell-mediated natural cytotoxicity. Brumbaugh, K.M., Binstadt, B.A., Billadeau, D.D., Schoon, R.A., Dick, C.J., Ten, R.M., Leibson, P.J. J. Exp. Med. (1997) [Pubmed]
  6. ZAP-70 tyrosine kinase is required for LFA-1-dependent T cell migration. Soede, R.D., Wijnands, Y.M., Van Kouteren-Cobzaru, I., Roos, E. J. Cell Biol. (1998) [Pubmed]
  7. Regulation of Akt-dependent cell survival by Syk and Rac. Jiang, K., Zhong, B., Ritchey, C., Gilvary, D.L., Hong-Geller, E., Wei, S., Djeu, J.Y. Blood (2003) [Pubmed]
  8. Lck is required for stromal cell-derived factor 1 alpha (CXCL12)-induced lymphoid cell chemotaxis. Inngjerdingen, M., Torgersen, K.M., Maghazachi, A.A. Blood (2002) [Pubmed]
  9. Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. Tolomeo, M., Grimaudo, S., Di Cristina, A., Roberti, M., Pizzirani, D., Meli, M., Dusonchet, L., Gebbia, N., Abbadessa, V., Crosta, L., Barucchello, R., Grisolia, G., Invidiata, F., Simoni, D. Int. J. Biochem. Cell Biol. (2005) [Pubmed]
  10. The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor alpha in human breast cancer cells. Maggiolini, M., Recchia, A.G., Bonofiglio, D., Catalano, S., Vivacqua, A., Carpino, A., Rago, V., Rossi, R., Andò, S. J. Mol. Endocrinol. (2005) [Pubmed]
  11. Calcium signaling in endothelial cells involves activation of tyrosine kinases and leads to activation of mitogen-activated protein kinases. Fleming, I., Fisslthaler, B., Busse, R. Circ. Res. (1995) [Pubmed]
  12. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. Bharadwaj, D., Mold, C., Markham, E., Du Clos, T.W. J. Immunol. (2001) [Pubmed]
  13. Shiga toxin regulates its entry in a Syk-dependent manner. Lauvrak, S.U., Wälchli, S., Iversen, T.G., Slagsvold, H.H., Torgersen, M.L., Spilsberg, B., Sandvig, K. Mol. Biol. Cell (2006) [Pubmed]
  14. Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells. Mahabeleshwar, G.H., Kundu, G.C. J. Biol. Chem. (2003) [Pubmed]
  15. Differential activation of human platelets induced by Fc gamma receptor II cross-linking and by anti-CD9 monoclonal antibody. Qi, R., Ozaki, Y., Kuroda, K., Asazuma, N., Yatomi, Y., Satoh, K., Nomura, S., Kume, S. J. Immunol. (1996) [Pubmed]
  16. Syk activation initiates downstream signaling events during human polymorphonuclear leukocyte phagocytosis. Raeder, E.M., Mansfield, P.J., Hinkovska-Galcheva, V., Shayman, J.A., Boxer, L.A. J. Immunol. (1999) [Pubmed]
  17. Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. Ashikawa, K., Majumdar, S., Banerjee, S., Bharti, A.C., Shishodia, S., Aggarwal, B.B. J. Immunol. (2002) [Pubmed]
  18. Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. Oliver, J.M., Burg, D.L., Wilson, B.S., McLaughlin, J.L., Geahlen, R.L. J. Biol. Chem. (1994) [Pubmed]
  19. Crystal-induced neutrophil activation. VII. Involvement of Syk in the responses to monosodium urate crystals. Desaulniers, P., Fernandes, M., Gilbert, C., Bourgoin, S.G., Naccache, P.H. J. Leukoc. Biol. (2001) [Pubmed]
  20. Tumor necrosis factor-alpha activation of the c-Jun N-terminal kinase pathway in human neutrophils. Integrin involvement in a pathway leading from cytoplasmic tyrosine kinases apoptosis. Avdi, N.J., Nick, J.A., Whitlock, B.B., Billstrom, M.A., Henson, P.M., Johnson, G.L., Worthen, G.S. J. Biol. Chem. (2001) [Pubmed]
  21. Enhanced phagocytosis through inhibition of de novo ceramide synthesis. Hinkovska-Galcheva, V., Boxer, L., Mansfield, P.J., Schreiber, A.D., Shayman, J.A. J. Biol. Chem. (2003) [Pubmed]
  22. Signal transduction involved in MCP-1-mediated monocytic transendothelial migration. Cambien, B., Pomeranz, M., Millet, M.A., Rossi, B., Schmid-Alliana, A. Blood (2001) [Pubmed]
  23. Activating and inhibitory Ly49 receptors modulate NK cell chemotaxis to CXC chemokine ligand (CXCL) 10 and CXCL12. Inngjerdingen, M., Rolstad, B., Ryan, J.C. J. Immunol. (2003) [Pubmed]
  24. MEK/ERK and signal transducer and activator of transcription signaling pathways modulate oncostatin M-stimulated CCL2 expression in human osteoblasts through a common transcription factor. Lin, S.K., Kok, S.H., Yeh, F.T., Kuo, M.Y., Lin, C.C., Wang, C.C., Goldring, S.R., Hong, C.Y. Arthritis Rheum. (2004) [Pubmed]
  25. Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. Su, L., David, M. J. Biol. Chem. (2000) [Pubmed]
  26. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Alas, S., Bonavida, B. Clin. Cancer Res. (2003) [Pubmed]
  27. Piceatannol in combination with low doses of cyclosporine A prolongs kidney allograft survival in a stringent rat transplantation model. Fernandez, L.A., Torrealba, J., Yagci, G., Ishido, N., Tsuchida, M., Tae Kim, H., Dong, Y., Oberley, T., Fechner, J., Colburn, M.J., Schultz, J., Kanmaz, T., Hu, H., Knechtle, S.J., Hamawy, M.M. Transplantation (2002) [Pubmed]
  28. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Potter, G.A., Patterson, L.H., Wanogho, E., Perry, P.J., Butler, P.C., Ijaz, T., Ruparelia, K.C., Lamb, J.H., Farmer, P.B., Stanley, L.A., Burke, M.D. Br. J. Cancer (2002) [Pubmed]
  29. Oncostatin M causes VEGF release from human airway smooth muscle: synergy with IL-1beta. Faffe, D.S., Flynt, L., Mellema, M., Whitehead, T.R., Bourgeois, K., Panettieri, R.A., Silverman, E.S., Shore, S.A. Am. J. Physiol. Lung Cell Mol. Physiol. (2005) [Pubmed]
WikiGenes - Universities